ÂÜÀòÂÒÂ×

Gary Glick serves as a Scientific Advisor for Aktis Oncology. Gary is the founder of IFM Therapeutics, where he currently serves as the Executive Chair, and has played a key role in the foundation and development of several other biotech companies including Lycera Corp, where he served as Chief Scientific Officer and Scorpion Therapeutics, where he served as Chief Executive Officer. He has over 30 years of experience in leading the discovery and development of therapies in academia and biopharma and is the author of more than 100 papers, the inventor of 48 issued U.S. patents and the recipient of numerous awards recognizing his scientific contributions and accomplishments as a life science executive. He started his career as a faculty member at the University of Michigan in Ann Arbor, where he is currently the Werner E. Bachmann Emeritus Professor of Chemistry.

Gary holds a PhD in organic chemistry from Columbia University and was an NIH post-doctoral fellow at Harvard University.